NASDAQ: SILO - Silo Pharma, Inc.

Yield per half year: -50.49%
Sector: Healthcare

Share chart Silo Pharma, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

Silo Pharma. Inc., a developmental stage biopharmaceutical company, focuses on merging traditional therapeutics with psychedelic research. The company's developing solutions to address various underserved conditions. It also seeks to acquire and/or develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the benefits they may have in certain cases involving depression, mental health issues, and neurological disorders.

More details
The company focuses on merging traditional therapeutics with psychedelic research for people suffering from indications, such as depression, post-traumatic stress disorder, Alzheimer's, Parkinson's, and other rare neurological disorders. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Цена ао 1.94
Выручка 4.1E-5
EBITDA -0.000902
Число акций ао 0.00308 млрд
P/E 3.5
P/S 219.82
P/BV -389.57
EV/EBITDA -9.83
Сайт https://silopharma.com
Валюта usd
IPO date 2014-05-13
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Change price per day: -3.77% (1.06)
Change price per week: -3.77% (1.06)
Change price per month: -9.73% (1.13)
Change price per 3 month: +5.92% (0.963)
Change price per half year: -50.49% (2.06)
Change price per year: -36.25% (1.6)
Change price per 3 year: +466.67% (0.18)
Change price per 5 year: +12 339.02% (0.0082)
Change price per year to date: -40% (1.7)
All parameters

Underestimation

Title Value Grade
P/S 68.34 1
P/BV 0.7978 9
P/E 0 0
EV/EBITDA -0.364 0
Total: 4.63

Efficiency

Title Value Grade
ROA, % -47.77 0
ROE, % -59.91 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA 0 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % 75.86 8
Yield Ebitda, % 327.45 10
Yield EPS, % -46.12 0
Total: 7.6
More

Institutions Volume Share, %
Financial Advocates Investment Management 62807 0.06
UBS Group AG 32843 0.03
Vanguard Group Inc 16334 0.02
Geode Capital Management, LLC 16179 0.02
TWO SIGMA SECURITIES, LLC 12788 0.01
State Street Corporation 12500 0.01
Tower Research Capital LLC (TRC) 7007 0.01
Westside Investment Management, Inc. 94 0
FWL INVESTMENT MANAGEMENT, LLC 80 0
Wells Fargo & Company 20 0

ETF Share, % Profitability for 1 year, % Dividends, %
Avantis Emerging Markets Equity ETF 0.00003 11.542669584245 3.60513
Dimensional Emerging Markets Core Equity 2 ETF 0.00246 15.961857379768 3.34087
Dimensional Emerging Markets Value ETF 0.00004 17.066115702479 4.19508
SPDR S&P Emerging Markets Small Cap ETF 0.01392 9.4592150479291 3.03583
FlexShares Morningstar Emerging Markets Factor Tilt Index Fund 0.00179 12.462475271255 3.59676



Head Job title Payment Year of birth
Mr. Eric Weisblum Chairman, President & CEO 569.01k 1970 (54 years)
Mr. Daniel E. Ryweck Chief Financial Officer 62.69k 1965 (59 years)
Dr. James S. Kuo M.B.A., M.D. Vice President of Research & Development N/A 1965 (59 years)

Address: United States, Englewood Cliffs. NJ, 560 Sylvan Avenue - open in Google maps, open in Yandex maps
Website: https://silopharma.com